All assays developed at BluSense are based on the Immuno-magnetic assay (IMA) patented opto-magnetic readout technique. IMA is a novel methodology to quantitatively measure the presence of biomarkers (antigens and/or antibodies) into a biological matrix based on aggregation of magnetic nanoparticles.
When running a test, blood flows into micro-fluidic channels, where plasma is separated from red blood cells by centrifugation. Plasma is then transferred into the reaction and readout chambers, where it dissolves the reagents, blocking buffer and dry magnetic nanoparticles. Magnetic nanoparticles, coated with a specific antigen or antibody, trap the target analyte. A magnetic field is then repeatedly applied to align the nanoparticles into chains and to increase the chains in size and in number.
Finally, a blue laser light is shone through the sample while an oscillating magnetic field is applied. In a negative sample, single particles do not produce a measurable signal. In a positive sample, nanoparticle chains rotate, scattering the light and producing a signal. The more the analyte, the more the nanoclusters, the higher the signal.
Automated plasma separation
Homogeneous format, no washing needed
Magnetic enhanced reaction
Rapid and quantitative patented IMA readout
Enabled by automation and robotized processes, our high-capacity production and packaging line is capable of delivering products at a high speed and with consistent quality.
The high level of automation and low dependence on human factors serve to maximize quality and maintain high quantities of finished cartridges.
To achieve this, we have invested in state-of-art robots, and optimized production by adding capacity to alleviate bottlenecks to achieve higher throughput of cartridges.
Built for flexibility our production line is a core-element of our business growth enabling us to do rapid prototyping of small batches for research purposes, while still fully supporting commercial demand.